Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats

Journal of Clinical Investigation

Volumn 98, Issue 3, 1996, Pages 671-679

  Volpert, Olga V ^a   Ward, William F ^a   Lingen, Mark W ^a   Chesler, Louis ^a   Solt, Dennis B ^a   Johnson, Mark D ^a,c   Molteni, Agostino ^a   Polverini, Peter J ^b   Bouck, Noël P ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF MICHIGAN SCHOOL OF DENTISTRY   (United States)

^c U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

Author keywords

captopril; chemotaxis; endothelial cells; gelatinases; neovascularization

Indexed keywords

CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LISINOPRIL;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; DOSE RESPONSE; ENZYME INHIBITION; EXPERIMENTAL NEOPLASM; MITOSIS; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0029916051     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI118838     Document Type: Article

References (53)

1. Migdalof, B H., M.J. Antonaccio, D.N. McKinstry, S.M. Singhvi, S.-J. Lan, F. Egli, and K.J. Kripalani. 1984. Captopril: pharmacology, metabolism, and disposition. Drug Metab. Rev. 15:841-869.
2. Materson, B.J., and R.A. Preston. 1994. Angiotensin-converting enzyme inhibitors in hypertension. Arch. Intern. Med. 154:513-523.
3. Pfeffer, M.A., E. Braunwald, L.A. Moye, L. Basta, E.J. Brown, T.E. Cuddy, B.R. Davis, E.M. Geltman, S. Goldman, G.C. Flaker, et al. 1992. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. 327:669-677.
4. Burris, J.F. 1995. The expanding role of angiotensin converting enzyme inhibitors in the management of hypertension. J. Clin. Pharmacol 35:337-342.
5. Garg, R., and S. Yusuf, for the Collaborative Group on ACE Inhibitor Trials. 1995. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. J. Am. Med. Assoc. 273:1450-1456.
6. Martin, M.F.R., K.E. Surrall, F. McKenna, J.S. Dixon, H.A. Bird, and V. Wright. 1984, Captopril: a new treatment for rheumatoid arthritis? Lancet i(8390): 1325-1328.
7. Jackson, W.E., D.L. Holmes, S.K. Garg, S. Harris, and H.P. Chase. 1992. Angiotensin-converting enzyme inhibitor therapy and diabetic retinopathy. Ann. Opthalmol. 24:99-103.
8. Collins, R., R. Peto, M. Flather, S. Parish, P. Sleight, M. Conway, A. Pipilis, C. Baigent, D. Barnett, J.P. Boissel, et al. 1995. ISIS-4A randomized factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet. 345:669-685.
9. Young, J.B. 1994. Angiotensin-converting enzyme inhibitors in heart failure: new strategies justified by recent clinical trials. Int. J. Cardiol. 43:151-163.
10. Chobanian, A.V., C.C. Haudenschild, C. Nickerson, and R. Drago. 1990. Antiatherogenic effect of captopril in the watanabe heritable hyperlipidemic rabbit. Hypertension (Dallas). 15:327-331.
11. Ashab, I., G. Peer, M. Blum, Y. Wollman, T. Chernihovsky, A. Hassner, D. Schwartz, S. Cabili, D. Silverberg, and A. Iaina. 1995. Oral administration of L-arginine and captopril in rats prevents chronic renal failure by nitric oxide production. Kidney Int. 47:1515-1521.
12. Lewis, E.J. 1995. Captopril and diabetic nephropathy. J. Am. Med. Assoc. 273:1831.
13. Ward, W.F., Y.T. Kim, A. Molteni, and N.M. Solliday. 1988. Radiation-induced pulmonary endothelial dysfunction in rats: modification by an inhibitor of angiotensin converting enzyme. Int. J. Radiat. Oncol. Biol. Phys. 15:135-140.
14. Ward, W.F., A. Molteni, C. Ts'ao, and J.M. Hinz. 1990. The effect of captopril on benign and malignant reactions in irradiated rat skin. Brit. J. Radiol. 63:349-354.
15. Folkman, J., and M. Klagsbrun. 1987. Angiogenic Factors. Science (Wash. DC). 235:442-447.
16. Wang, D.-H., and R.L. Prewitt. 1990. Captopril reduces aortic and microvascular growth in hypertensive and normotensive rats. Hypertension (Dallas). 15:68-77.
17. Fernandez, L.A., J. Twickler, and A. Mead. 1985. Neovascularization produced by angiotensin II. J. Lab. Clin. Med. 105:141-145.
18. Le Noble, F.A., J.W. Hekking, H.W. Van Straaten, D.W. Slaaf, and H. A. Struyker-Boudier. 1991. Angiotensin II stimulates angiogenesis in the chorio-allantoic membrane of the chick embryo. Eur. J. Pharmacol. 195:305-306.
19. Le Noble, F.A.C., N.H.J.S. Schreurs, H.W.M. Van Straaten, D.W. Slaaf, J.F.M. Smits, H. Rogg, and H.A. Struijker-Boudier. 1993. Evidence for a novel angiotensin II receptor involved in angiogenesis in chick embryo chorioallantoic membrane. Am. J. Physiol. 264:R460-R465.
20. Hernandez, I., A.W. Cowley, Jr., J.H. Lombard, and A.S. Greene. 1992. Salt intake and angiotensin II alter microvessel density in the cremaster muscle of normal rats. Am. J Physiol. 263:H8664-H8667.
21. Tolsma, S.S., O.V. Volpert, D.J. Good, W.F. Frazier, P.J. Polverini, and N. Bouck. 1993. Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity. J. Cell Biol. 122:497-511.
22. Polverini, P.J., N.P. Bouck, and F. Rastinejad. 1991. Assay and purification of a naturally occurring inhibitor of angiogenesis. Methods Enzymol. 198: 440-450.
23. Herron, G.S., M.J. Band, E.J. Clark, J. Gavrilovic, and Z. Werb. 1986. Secretion of metalloproteinases by stimulated capillary endothelial cells. II. Expression of collagenase and stromelysin activities is regulated by endogenous inhibitors. J. Biol. Chem. 261:2841-2848.
24. Liotta, L.A., K. Tryggvason, S. Garbisa, P.G. Robey, and S. Abe. 1981. Partial purification and characterization of a neutral protease which cleaves type IV collagen. Biochemistry. 20:100-104.
25. Solt, D., and E. Farber. 1976. New principle for the analysis of chemical carcinogenesis. Nature (Lond). 263:701-703.
26. Polverini, P.J., and S.J. Leibovich. 1984. Induction of neovascularization in vivo and endothelial proliferation in vitro by tumor-associated macrophages. Lab. Invest. 51:635-642.
27. Zetler, B.R. 1987. Assay of capillary endothelial cell migration. Methods Enzymol. 147:135-144.
28. Bouck, N., V. Stellmach, and S. Hsu. 1996. How tumors become angiogenic. Adv. Cancer Res. 69:135-174.
29. Mansfield, P.J., L.A. Boxer, and S.J. Suchard. 1990. Thrombospondin stimulates motility of human neutrophils. J. Cell Biol. 111:3077-3086.
30. Duchin, K.L., D.N. McKinstry, A.I. Cohen, and B.H. Migdalof. 1988. Pharmacokinetics of captopril in healthy subjects and in patients with cardiovascular diseases. Clin. Pharmacokinet. 14:241-259.
31. c-src expression. J. Clin. Invest. 89:315-320.
32. Matsubara, T., R. Saura, K. Hirohata, and M. Ziff. 1989. Inhibition of human endothelial cell proliferation in vitro and neovascularization in vivo by D-penicillamine. J. Clin. Invest. 83:158-167.
33. Sorbi, D., M. Fadly, R. Hicks, S. Alexander, and L. Arbeit. 1993. Captopril inhibits the 72 kDa and 92 kDa matrix metalloproteinases. Kidney Int. 44: 1266-1272.
34. Palatini, P., F. Dabbeni-Sala, and P. Finotti. 1989. Inhibition of dopamine β-hydroxylase by captopril. Biochem. Pharmacol. 38:1011-1013.
35. 4 hydrolase/aminopeptidase by captopril. J. Biol. Chem. 266:16507-16511.
36. Takahashi, M., Y. Matsushita, Y. Iijima, and K. Tanzawa. 1993. Purification and characterization of endothelin-converting enzyme from rat lung. J. Biol. Chem. 268:21394-21398.
37. Emoto, N., and M. Yanagisawa. 1995. Endothelin-converting enzyme-2 is a membrane-bound, phosphoramidon-sensitive metalloprotease with acidic pH optimum. J. Biol. Chem. 270:15262-15268.
38. Ahn, K., S. Pan, K. Beningo, and D. Hupe. 1995. A permanent human cell line (EA.HY926) preserves the characteristics of endothelin converting enzyme from primary human umbilical vein endothelial cells. Life Sci. 56:2331-2341.
39. Murphy, A.N., E.J. Unsworth, and W.G. Stetler-Stevenson. 1993. Tissue inhibitor of metalloproteinases-2 inhibits bFGF-induced human microvascular undothelial cell proliferation. J. Cell. Physiol. 157:351-358.
40. Fisher, C. S. Gilbertson-Beadling, E.A. Powers, G. Petzold, R. Poorman, and M.A. Mitchell. 1994. Interstitial collagenase is required for angiogenesis in vitro. Dev. Biol. 162:499-510.
41. Takigawa, M., Y. Nishida, F. Suzuki, J. Kishi, K. Yamashita, and T. Hayakawa. 1990. Induction of angiogenesis in chick yolk-sac membrane by polyamines and its inhibition by tissue inhibitors of metalloproteinases (TIMP and TIMP-2). Biochem. Biophys. Res. Commun. 171:1264-1271.
42. Moses, M.A., J. Sudhalter, and R. Langer. 1990. Identification of an inhibitor of neovascularization from cartilage. Science (Wash. DC). 248:1408-1410.
43. Moses, M.A., J. Sudhalter, and R. Langer. 1992. Isolation and characterization of an inhibitor of neovascularization from scapular chondrocytes. J. Cell Biol. 119:475-482.
44. Folkman, J. 1990. What is the evidence that tumors are angiogenesis dependent? J. Natl. Cancer Inst. 82:4-6.
45. Tannock, I. 1970. Population kinetics of carcinoma cells, capillary endothelial cells and fibroblasts in a transplanted mouse mammary tumor. Cancer Res. 30:2470-2476.
46. Kohama, Y., H. Oka, N, Murayama, K. Iida, M. Itoh, X. Ying, and T. Mimura. 1992. Increase of migration of cultured endothelial cells by angiotensin-converting enzyme inhibitor derived from tuna muscle. J. Pharmacobio.-Dyn. 15:223-229.
47. Bell, L., and J.A. Madri. 1990. Influence of the angiotensin system on endothelial and smooth muscle cell migration. A. J. Pathol. 137:7-12.
48. Tsuboi, R., Y. Sato, and D.B. Rifkin. 1990. Correlation of cell migration, cell invasion, receptor number, proteinase production, and basic fibroblast growth factor levels in endothelial cells. J. Cell Biol. 110:511-517.
49. Zusman, R.M. 1987. Effects of converting-enzyme inhibitors on the renin-angiotensin-aldosterone, bradykinin and arachidonic acid-prostaglandin systems: correlation of chemical structure and biologic activity. Am. J. Kidney Dis. Suppl.X:13-23.
50. Guivernau, M., F. Armijo, and R. Rosas. 1991. Role of sulfhydryl groups in the stimulatory effect of captopril on vascular prostacyclin synthesis. Eur. J. Pharmacol. 198:1-6.
51. Warren, J.B., and R.K. Loi. 1995. Captopril increases skin microvascular blood flow secondary to bradykinin, nitric oxide, and prostaglandins. FASEB J. 9:411-418.
52. Guest, I., H.S. Buttar, S. Smith, and D.R. Varma. 1994. Evaluation of the rat embryo culture system as a predictive test for human teratogens. Can. J. Physiol. Pharmacol. 72:57-62.
53. Kreft-Jais, C., P.-F. Plouin, C. Tchobroutsky, and J. Boutroy. 1988. Angiotensin-converting enzyme inhibitors during pregnancy: a survey of 22 patients given captopril and nine given enalapril. Br. J. Obstet. and Gynaecol. 95: 420-422.